Kevin Harrington (@kevhar6763) / Twitter
The Institute of Cancer Research - Professor Kevin Harrington (ICR + Royal Marsden NHS Foundation Trust) responds to today's news of the 2018 Nobel Prize for Physiology or Medicine being awarded to
Game-changing drug doubles head and neck cancer survival | The Royal Marsden
Scientific Advisory Board – PsiVac
Game-changing drug doubles head and neck cancer survival | The Royal Marsden
Kevin Harrington | Oncologist in Sutton - Doctify
Kevin Harrington | Oncologist in Sutton - Doctify
Potential of immunotherapy in head and neck cancer | VJOncology
Will Immunotherapy Put Head and Neck Surgeons Out of Business? – Semon Lectures
Professor Kevin Harrington - The Institute of Cancer Research, London
Royal Marsden staff among world's top influential researchers | The Royal Marsden Cancer Charity
Descifrando la complejidad clínica del cáncer de cabeza y cuello – Fundación ECO para la Excelencia y Calidad en la Oncología
Royal Marsden researchers named among world's most influential scientists | The Royal Marsden
Potential of immunotherapy in head and neck cancer | VJOncology
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - News, Articles etc. - European Pharmaceutical Review
Cancer: Scientists aim to double survival within a decade | The Independent
Professor Kevin Harrington | The Royal Marsden
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London
Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile
Potential of immunotherapy in head and neck cancer | VJOncology
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube
Potential of immunotherapy in head and neck cancer | VJOncology
My final lifeline" | The Biomedical Scientist Magazine of the IBMS
Professor Kevin Harrington - The Institute of Cancer Research, London
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
